COVID-19对哮喘患者的影响:大数据分析
哮喘合并COVID-19者年龄更大、女性更多、合并症更多,过敏相关因素较少;住院患者ICS使用率较低(48.3% vs 61.5%,OR 0.58,95%CI 0.44-0.77),生物制剂治疗者COVID-19住院率较低(0.23%)。
要点
- 哮喘合并COVID-19患者年龄更大、合并症更多,过敏因素较少。
- 住院患者ICS使用率较低,提示ICS可能具保护作用。
- 生物制剂治疗者COVID-19相关住院率较低(0.23%)。
核心结论
- 哮喘合并COVID-19患者年龄更大且因合并症因素风险增加。
- ICS和生物制剂通常安全,可能与针对重症COVID-19的保护效应相关。
研究设计与样本
- 利用SAVANA Manager临床平台的大数据分析和人工智能,分析2020年1月1日至5月10日哮喘患者临床数据。
主要发现
- 哮喘合并COVID-19患者较无COVID-19者年龄更大(55岁 vs 42岁),女性更多(66% vs 59%),吸烟更频繁,高血压、血脂异常、糖尿病和肥胖患病率更高。
- 过敏性鼻炎和湿疹等过敏相关因素在哮喘合并COVID-19患者中较少见(p<0.001)。
- 需住院的COVID-19患者中上述合并症患病率更高。
- 因COVID-19住院患者ICS使用率低于非住院患者(48.3% vs 61.5%;OR 0.58,95%CI 0.44-0.77)。
- 接受生物制剂治疗者(n=865;1.21%)虽病情更重且耳鼻喉科合并症更多,但COVID-19相关住院率相对较低(0.23%)。
关键数值与推荐
- 住院患者ICS使用率48.3% vs 非住院患者61.5%,OR 0.58(95%CI 0.44-0.77)。
- 生物制剂治疗者COVID-19相关住院率为0.23%。
临床怎么用
- 哮喘患者感染COVID-19时需关注年龄及合并症(高血压、糖尿病、肥胖等)带来的风险。
- ICS和生物制剂在哮喘患者中通常安全,不应因担心COVID-19而停用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An association between the severity of coronavirus disease 2019 (COVID-19) and the presence of certain chronic conditions has been suggested. However, unlike influenza and other viruses, the disease burden of COVID-19 in patients with asthma has been less evident. OBJECTIVE: To understand the impact of COVID-19 in patients with asthma. METHODS: Using big-data analytics and artificial intelligence through the SAVANA Manager clinical platform, we analysed clinical data from patients with asthma from January 1 to May 10, 2020. RESULTS: Out of 71 182 patients with asthma, 1006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 versus 42 years), predominantly female (66% versus 59%), smoked more frequently and had higher prevalence of hypertension, dyslipidaemias, diabetes and obesity. Allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19 (p<0.001). In addition, higher prevalence of these comorbidities was observed in patients with COVID-19 who required hospital admission. The use of inhaled corticosteroids (ICS) was lower in patients who required hospitalisation due to COVID-19, as compared to non-hospitalised patients (48.3% versus 61.5%; OR 0.58, 95% CI 0.44-0.77). Although patients treated with biologics (n=865; 1.21%) showed increased severity and more comorbidities at the ear, nose and throat level, COVID-19-related hospitalisations in these patients were relatively low (0.23%). CONCLUSION: Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.
引用
- Izquierdo JL, Almonacid C, González Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021. PMID: 33154029. doi:10.1183/13993003.03142-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。